Tango Therapeutics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:TNGX
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 504 out of 914
Universe
Global Universe 11146 out of 16048
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
PolyPeptide Group AG |
21.3
Medium
|
117 out of 914 |
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. |
25.7
Medium
|
256 out of 914 |
Keymed Biosciences, Inc. |
27.8
Medium
|
401 out of 914 |
GuangYuYuan Chinese Herbal Medicine Co., Ltd. |
27.9
Medium
|
412 out of 914 |
Tango Therapeutics, Inc. |
29.6
Medium
|
504 out of 914 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Tango Therapeutics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Tango Therapeutics, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Tango Therapeutics, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level